Jack Allen
Stock Analyst at Baird
(1.59)
# 3,460
Out of 5,008 analysts
43
Total ratings
42.42%
Success rate
-5.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jack Allen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TSHA Taysha Gene Therapies | Maintains: Outperform | $7 → $12 | $4.72 | +154.24% | 5 | Oct 2, 2025 | |
| VOR Vor Biopharma | Maintains: Neutral | $5 → $20 | $33.80 | -40.83% | 4 | Jun 27, 2025 | |
| FATE Fate Therapeutics | Maintains: Neutral | $5 → $4 | $1.39 | +187.77% | 2 | May 14, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Outperform | $12 → $9 | $1.35 | +566.67% | 3 | May 14, 2025 | |
| CARM Carisma Therapeutics | Downgrades: Neutral | $10 → $1 | $0.26 | +281.10% | 3 | Dec 12, 2024 | |
| INKT MiNK Therapeutics | Maintains: Outperform | $80 → $40 | $14.90 | +168.46% | 2 | Nov 15, 2024 | |
| ACLX Arcellx | Maintains: Outperform | $77 → $106 | $85.21 | +24.40% | 5 | Nov 6, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $24 → $18 | $20.44 | -11.94% | 2 | Oct 25, 2024 | |
| TIL Instil Bio | Reiterates: Outperform | $180 | $18.58 | +868.78% | 9 | Sep 16, 2024 | |
| MREO Mereo BioPharma Group | Initiates: Outperform | $8 | $1.95 | +310.26% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $52 | $70.62 | -26.37% | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $84 | $34.22 | +145.47% | 1 | Oct 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $1.73 | +189.02% | 1 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $3.82 | - | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $6 → $9 | $4.73 | +90.27% | 1 | Oct 7, 2021 |
Taysha Gene Therapies
Oct 2, 2025
Maintains: Outperform
Price Target: $7 → $12
Current: $4.72
Upside: +154.24%
Vor Biopharma
Jun 27, 2025
Maintains: Neutral
Price Target: $5 → $20
Current: $33.80
Upside: -40.83%
Fate Therapeutics
May 14, 2025
Maintains: Neutral
Price Target: $5 → $4
Current: $1.39
Upside: +187.77%
Allogene Therapeutics
May 14, 2025
Maintains: Outperform
Price Target: $12 → $9
Current: $1.35
Upside: +566.67%
Carisma Therapeutics
Dec 12, 2024
Downgrades: Neutral
Price Target: $10 → $1
Current: $0.26
Upside: +281.10%
MiNK Therapeutics
Nov 15, 2024
Maintains: Outperform
Price Target: $80 → $40
Current: $14.90
Upside: +168.46%
Arcellx
Nov 6, 2024
Maintains: Outperform
Price Target: $77 → $106
Current: $85.21
Upside: +24.40%
Intellia Therapeutics
Oct 25, 2024
Maintains: Neutral
Price Target: $24 → $18
Current: $20.44
Upside: -11.94%
Instil Bio
Sep 16, 2024
Reiterates: Outperform
Price Target: $180
Current: $18.58
Upside: +868.78%
Mereo BioPharma Group
Jun 13, 2024
Initiates: Outperform
Price Target: $8
Current: $1.95
Upside: +310.26%
May 9, 2024
Maintains: Neutral
Price Target: $46 → $52
Current: $70.62
Upside: -26.37%
Oct 31, 2023
Initiates: Outperform
Price Target: $84
Current: $34.22
Upside: +145.47%
Nov 2, 2022
Initiates: Outperform
Price Target: $5
Current: $1.73
Upside: +189.02%
May 18, 2022
Upgrades: Outperform
Price Target: n/a
Current: $3.82
Upside: -
Oct 7, 2021
Upgrades: Outperform
Price Target: $6 → $9
Current: $4.73
Upside: +90.27%